Lisa Martina

Business Account Executive @Alnylam Pharmaceuticals

Hypernova winner, TTR division 2022 Hypernova winner, TTR division 2021 Ranked # 7, TTR division, 2022 • Rare Disease: Drive patient identification, market development in hereditary Transthyretin-mediated amyloidosis by building and executing against a territory strategy and account specific plans. • Launch the first approved small interfering RNA product and establish infusion sites of care to treat appropriate patients. • Collaborate with key accounts and physicians to drive patient identification through market development and physician education; post launch was able to develop a territory strategy to retain customers. • Executes programs and in-services for territory across multiple account types: clinics, infusion centers, etc Member of Hispanic/Latin X ERN